Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

Willburger, RE; Wittenberg, RH; BrauckmannBerger, J; Kleemeyer, KS; Hoos, R; Ludwig, J; Brunner, F; Peskar, BA.
Level of leukotriene and thromboxane in blood and clinical parameters of patients with osteoarthritis and rheumatoid arthritis before and after application of tepoxalin
AKTUEL RHEUMATOL. 1996; 21(5): 238-241. Doi: 10.1055/s-2008-1043723
Web of Science FullText FullText_MUG

Co-authors Med Uni Graz: Peskar Bernhard
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: In a clinical study phase II 2 x 200 mg tepoxalin were administered orally over 3.5 days to 7 patients with osteoarthritis (OA) and 6 patients with rheumatoid arthritis (RA). Leukotriene (LT) B-4 and LTC(4) release from blood was decreased, thromboxane (TX) B-2 release was reduced significantly. Relevant concentrations of tepoxalin and its metabolite in plasma and synovial fluid were detectable. According to the visual analog scale, pain was reduced significantly for both groups. in RA patients, the Ritchie Index, the number of swollen joints, and morning stiffness were reduced.